The AmoyDx® Myeloid Blood Cancer Panel employs next-generation sequencing (NGS) technology to qualitatively detect and identify single nucleotide variants (SNVs), insertions and deletions (InDels), and gene fusions within 55 genes associated with myeloid leukemia. This assay utilizes DNA and RNA extracted from bone marrow aspirate specimens obtained from patients diagnosed with acute myeloid leukemia or chronic myeloid leukemia.
